Noncoding RNAs: Emerging Players in Muscular Dystrophies
Overview
Biotechnology
General Medicine
Affiliations
The fascinating world of noncoding RNAs has recently come to light, thanks to the development of powerful sequencing technologies, revealing a variety of RNA molecules playing important regulatory functions in most, if not all, cellular processes. Many noncoding RNAs have been implicated in regulatory networks that are determinant for skeletal muscle differentiation and disease. In this review, we outline the noncoding RNAs involved in physiological mechanisms of myogenesis and those that appear dysregulated in muscle dystrophies, also discussing their potential use as disease biomarkers and therapeutic targets.
Zhang Y, Chen J, He S, Xiao Y, Liu A, Zhang D Front Mol Biosci. 2022; 9:940290.
PMID: 36111133 PMC: 9470226. DOI: 10.3389/fmolb.2022.940290.
Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing.
Izzo M, Battistini J, Provenzano C, Martelli F, Cardinali B, Falcone G Int J Mol Sci. 2022; 23(9).
PMID: 35563013 PMC: 9101876. DOI: 10.3390/ijms23094622.
Cardinali B, Provenzano C, Izzo M, Voellenkle C, Battistini J, Strimpakos G Mol Ther Nucleic Acids. 2022; 27:184-199.
PMID: 34976437 PMC: 8693309. DOI: 10.1016/j.omtn.2021.11.024.
Regulatory Potential of Competing Endogenous RNAs in Myotonic Dystrophies.
Koscianska E, Kozlowska E, Fiszer A Int J Mol Sci. 2021; 22(11).
PMID: 34200099 PMC: 8201210. DOI: 10.3390/ijms22116089.
Dissecting the transcriptome in cardiovascular disease.
Robinson E, Baker A, Brittan M, McCracken I, Condorelli G, Emanueli C Cardiovasc Res. 2021; 118(4):1004-1019.
PMID: 33757121 PMC: 8930073. DOI: 10.1093/cvr/cvab117.